Pipeline
Innovative and creative portfolio across two pillars of growth: ADC and small molecule
Our Pipeline
ADC Products
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| Caxmotabart Entudotin HER2-MMAF | BC,GC,OC,UC |
|
|
-L/O for China |
|||||
|
|
|
-Multi solid cancer |
|||||||
|
|
|
-Breast cancer |
|||||||
| Caxmotabart Entudotin HER2-MMAF | BC,GC,LC |
|
|
- WW right |
|||||
| LCB71 (CS5001) ROR1-pPBD | CLL, MCL ,ALL, TNBC, NSCLC, Solid |
|
|
||||||
| LCB84 TROP2-MMAE | Solid, Heme |
|
|
||||||
| LCB73 CD19-pPBD | ALL, NHL, CLL, DLBCL |
|
|
||||||
| LCB97 L1CAM | Solid |
|
|
||||||
| LCB41A (LNCB74) B7H4-MMAE | Solid |
|
|
||||||
| LCB36 CD20XCD22-pPBD | Heme |
|
|
||||||
| LCB02A CLDN18.2 | Solid |
|
|
||||||
| SOT106 LRRC15 | Solid |
|
|
Partner's ADC arising from Platform deal |
|||||
| IKS04 CA242 | Solid |
|
|
Partner's ADC arising from Platform deal |
|||||
| IKS012 FOLR1 | Solid |
|
|
Partner's ADC arising from Platform deal |
|||||